1. |
Liu SY, Xu SY, Yin L, et al. Management of regional citrate anticoagulation for continuous renal replacement therapy: guideline recommendations from Chinese emergency medical doctor consensus. Mil Med Res, 2023, 10(1): 23.
|
2. |
Zarbock A, Küllmar M, Kindgen-Milles D, et al. Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically ill patients with acute kidney injury: a randomized clinical trial. JAMA, 2020, 324(16): 1629-1639.
|
3. |
Zhou Z, Liu C, Yang Y, et al. Anticoagulation options for continuous renal replacement therapy in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials. Crit Care, 2023, 27(1): 222.
|
4. |
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract, 2012, 120(4): c179-c184.
|
5. |
Li L, Bai M, Yu Y, et al. Regional citrate anticoagulation vs no-anticoagulation for CRRT in hyperlactatemia patients with increased bleeding risk: a retrospective cohort study. Semin Dial, 2021, 34(3): 209-217.
|
6. |
Li L, Bai M, Zhang W, et al. Regional citrate anticoagulation versus low molecular weight heparin for CRRT in hyperlactatemia patients: a retrospective case-control study. Int J Artif Organs, 2022, 45(4): 343-350.
|
7. |
Tang X, Chen D, Zhang L, et al. Application of regional citrate anticoagulation in patients at high risk of bleeding during intermittent hemodialysis: a prospective multicenter randomized controlled trial. J Zhejiang Univ Sci B, 2022, 23(11): 931-942.
|
8. |
van der Slikke EC, Star BS, van Meurs M, et al. Sepsis is associated with mitochondrial DNA damage and a reduced mitochondrial mass in the kidney of patients with sepsis-AKI. Crit Care, 2021, 25(1): 36.
|
9. |
Gao J, Wang F, Wang Y, et al. A mode of CVVH with regional citrate anticoagulation compared to no anticoagulation for acute kidney injury patients at high risk of bleeding. Sci Rep, 2019, 9(1): 6607.
|
10. |
Uusalo P, Järvisalo MJ. Mortality and renal prognosis in isolated metformin-associated lactic acidosis treated with continuous renal replacement therapy and citrate-calcium-anticoagulation. Acta Anaesthesiol Scand, 2020, 64(9): 1305-1311.
|
11. |
Kośka A, Kowalik MM, Lango-Maziarz A, et al. Ionic homeostasis, acid-base balance and the risk of citrate accumulation in patients after cardiovascular surgery treated with continuous veno-venous haemofiltration with post-dilution regional citrate anticoagulation - an observational case-control study. Acta Biochim Pol, 2021, 68(4): 695-704.
|
12. |
To HHM, Kwan AMC, Leung NYY, et al. A prospective study on serum citrate levels and clinical correlations in patients receiving regional citrate anticoagulation. Clin Kidney J, 2022, 16(2): 285-292.
|
13. |
郑燚, 孙献坤, 王芳, 等. 伴高乳酸血症连续性肾替代治疗患者应用局部枸橼酸抗凝的研究进展. 中华肾脏病杂志, 2024, 40(4): 325-329.
|
14. |
Khadzhynov D, Dahlinger A, Schelter C, et al. Hyperlactatemia, lactate kinetics and prediction of citrate accumulation in critically ill patients undergoing continuous renal replacement therapy with regional citrate anticoagulation. Crit Care Med, 2017, 45(9): e941-e946.
|
15. |
Tolwani A, Wille KM. Advances in continuous renal replacement therapy: citrate anticoagulation update. Blood Purif, 2012, 34(2): 88-93.
|
16. |
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA, 2016, 315(8): 801-810.
|
17. |
Kim SG, Lee J, Yun D, et al. Hyperlactatemia is a predictor of mortality in patients undergoing continuous renal replacement therapy for acute kidney injury. BMC Nephrol, 2023, 24(1): 11.
|
18. |
Tan JN, Haroon SWP, Mukhopadhyay A, et al. Hyperlactatemia predicts citrate intolerance with regional citrate anticoagulation during continuous renal replacement therapy. J Intensive Care Med, 2019, 34(5): 418-425.
|
19. |
Mohebbi N, Ritter A, Wiegand A, et al. Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial. Lancet, 2023, 401(10376): 557-567.
|
20. |
Emmett M. Metabolic alkalosis: a brief pathophysiologic review. Clin J Am Soc Nephrol, 2020, 15(12): 1848-1856.
|
21. |
Hundemer GL, Clarke A, Akbari A, et al. Analysis of electrolyte abnormalities in adolescents and adults and subsequent diagnosis of an eating disorder. JAMA Netw Open, 2022, 5(11): e2240809.
|
22. |
Arzhan S, Roumelioti ME, Litvinovich I, et al. Outcomes of hospital-acquired hypernatremia. Clin J Am Soc Nephrol, 2023, 18(11): 1396-1407.
|
23. |
Zhang W, Bai M, Zhang L, et al. Development and external validation of a model for predicting sufficient filter lifespan in anticoagulation-free continuous renal replacement therapy patients. Blood Purif, 2022, 51(8): 668-678.
|
24. |
Assefi M, Leurent A, Blanchard F, et al. Impact of increasing post-filter ionized calcium target on filter lifespan in renal replacement therapy with regional citrate anticoagulation: a before-and-after study. J Crit Care, 2023, 78: 154364.
|
25. |
Schultheiß C, Saugel B, Phillip V, et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care, 2012, 16(4): R162.
|
26. |
Slowinski T, Morgera S, Joannidis M, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Crit Care, 2015, 19: 349.
|
27. |
Kramer L, Bauer E, Joukhadar C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med, 2003, 31(10): 2450-2455.
|
28. |
Oudemans-van Straaten HM, Ostermann M. Bench-to-bedside review: citrate for continuous renal replacement therapy, from science to practice. Crit Care, 2012, 16(6): 249.
|